Spots Global Cancer Trial Database for ep4 antagonist
Every month we try and update this database with for ep4 antagonist cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | NCT04344795 | Solid Tumor Colorectal Canc... Non Small Cell ... Squamous Cell C... Urothelial Carc... Endometrial Can... Gastroesophagea... Gastric Adenoca... Solid Tumors Wi... | TPST-1495 twice... TPST-1495 once ... Pembrolizumab | 18 Years - | Tempest Therapeutics | |
A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients | NCT05205330 | Refractory Meta... Solid Tumor Metastatic Micr... Mismatch Repair... | CR6086 AGEN2034 | 18 Years - | Rottapharm Biotech | |
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | NCT04344795 | Solid Tumor Colorectal Canc... Non Small Cell ... Squamous Cell C... Urothelial Carc... Endometrial Can... Gastroesophagea... Gastric Adenoca... Solid Tumors Wi... | TPST-1495 twice... TPST-1495 once ... Pembrolizumab | 18 Years - | Tempest Therapeutics |